Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report

Since nucleoside-modified mRNA vaccines strongly activate T follicular helper cells, it is important to explore the possible impact of approved SARS-CoV-2 mRNA vaccines on neoplasms affecting this cell type. Herein, we report and discuss unexpected rapid progression of lymphomatous lesions after adm...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Serge Goldman, Dominique Bron, Thomas Tousseyn, Irina Vierasu, Laurent Dewispelaere, Pierre Heimann, Elie Cogan, Michel Goldman
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	mRNA vaccine T cell lymphoma COVID-19 angioimmunoblastic follicular Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/203b9a84312a421abc0475ff22e44518
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:203b9a84312a421abc0475ff22e44518
record_format	dspace
spelling	oai:doaj.org-article:203b9a84312a421abc0475ff22e445182021-12-01T01:29:27ZRapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report2296-858X10.3389/fmed.2021.798095https://doaj.org/article/203b9a84312a421abc0475ff22e445182021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmed.2021.798095/fullhttps://doaj.org/toc/2296-858XSince nucleoside-modified mRNA vaccines strongly activate T follicular helper cells, it is important to explore the possible impact of approved SARS-CoV-2 mRNA vaccines on neoplasms affecting this cell type. Herein, we report and discuss unexpected rapid progression of lymphomatous lesions after administration of a BNT162b2 mRNA vaccine booster in a man recently diagnosed with AITL.Serge GoldmanDominique BronThomas TousseynIrina VierasuLaurent DewispelaerePierre HeimannElie CoganMichel GoldmanFrontiers Media S.A.articlemRNA vaccineT celllymphomaCOVID-19angioimmunoblasticfollicularMedicine (General)R5-920ENFrontiers in Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	mRNA vaccine T cell lymphoma COVID-19 angioimmunoblastic follicular Medicine (General) R5-920
spellingShingle	mRNA vaccine T cell lymphoma COVID-19 angioimmunoblastic follicular Medicine (General) R5-920 Serge Goldman Dominique Bron Thomas Tousseyn Irina Vierasu Laurent Dewispelaere Pierre Heimann Elie Cogan Michel Goldman Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
description	Since nucleoside-modified mRNA vaccines strongly activate T follicular helper cells, it is important to explore the possible impact of approved SARS-CoV-2 mRNA vaccines on neoplasms affecting this cell type. Herein, we report and discuss unexpected rapid progression of lymphomatous lesions after administration of a BNT162b2 mRNA vaccine booster in a man recently diagnosed with AITL.
format	article
author	Serge Goldman Dominique Bron Thomas Tousseyn Irina Vierasu Laurent Dewispelaere Pierre Heimann Elie Cogan Michel Goldman
author_facet	Serge Goldman Dominique Bron Thomas Tousseyn Irina Vierasu Laurent Dewispelaere Pierre Heimann Elie Cogan Michel Goldman
author_sort	Serge Goldman
title	Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
title_short	Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
title_full	Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
title_fullStr	Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
title_full_unstemmed	Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report
title_sort	rapid progression of angioimmunoblastic t cell lymphoma following bnt162b2 mrna vaccine booster shot: a case report
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/203b9a84312a421abc0475ff22e44518
work_keys_str_mv	AT sergegoldman rapidprogressionofangioimmunoblastictcelllymphomafollowingbnt162b2mrnavaccineboostershotacasereport AT dominiquebron rapidprogressionofangioimmunoblastictcelllymphomafollowingbnt162b2mrnavaccineboostershotacasereport AT thomastousseyn rapidprogressionofangioimmunoblastictcelllymphomafollowingbnt162b2mrnavaccineboostershotacasereport AT irinavierasu rapidprogressionofangioimmunoblastictcelllymphomafollowingbnt162b2mrnavaccineboostershotacasereport AT laurentdewispelaere rapidprogressionofangioimmunoblastictcelllymphomafollowingbnt162b2mrnavaccineboostershotacasereport AT pierreheimann rapidprogressionofangioimmunoblastictcelllymphomafollowingbnt162b2mrnavaccineboostershotacasereport AT eliecogan rapidprogressionofangioimmunoblastictcelllymphomafollowingbnt162b2mrnavaccineboostershotacasereport AT michelgoldman rapidprogressionofangioimmunoblastictcelllymphomafollowingbnt162b2mrnavaccineboostershotacasereport
_version_	1718405947425030144

Rapid Progression of Angioimmunoblastic T Cell Lymphoma Following BNT162b2 mRNA Vaccine Booster Shot: A Case Report

Ejemplares similares